Shire Sues Alkem Over Fosrenol Patents

Law360, New York (January 13, 2011, 4:30 PM EST) -- Pharmaceutical giant Shire Canada Inc. has launched two parallel infringement suits against Alkem Laboratories Ltd. over its bid to introduce a generic version of kidney failure treatment Fosrenol.

The Ireland-based drugmaker's Canada and U.S. divisions filed two complaints on Wednesday in the U.S. District Courts for the Northern District of Illinois and the Southern District of New York, alleging infringement of two Fosrenol patents.

Alkem filed an abbreviated new drug application with the FDA in December, requesting to market lanthanum carbonate chewable tablets, the generic equivalent...
To view the full article, register now.